Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Belantamab mafodotin in R/R myeloma and methods of reducing ocular toxicity

Rakesh Popat • 10 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Belantamab mafodotin
DREAMM-2

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the efficacy of belantamab mafodotin in relapsed/refractory multiple myeloma (R/R MM) and efforts to limit the ocular toxicity associated with this agent. Dr Popat explains how active surveillance and treatment interruptions are important, and that obtaining information directly from patients with questionnaires may also help with predicting keratopathy and guiding treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals